In conclusion, our work confirmed the role of ALDOC as a promoter in NSCLC, and its interaction with UBE2N regulates the development and progression of NSCLC, suggesting ALDOC as a potential therapeutic target for NSCLC. Here, UBE2N is linked to non-small cell lung carcinoma.